Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vinorelbine liposome is a liposomal formulation of vinorelbine, an antimitotic anticancer agent belonging to the vinca alkaloid class. It functions by inhibiting microtubule dynamics, which leads to mitotic arrest and subsequent cell death. The liposomal encapsulation aims to reduce systemic toxicity, enhance tumor tissue targeting, and improve the pharmacokinetic profile compared to conventional vinorelbine. It has been investigated for various cancers, including advanced solid tumors, non-Hodgkin's lymphoma, Hodgkin's disease, non-small cell lung cancer, breast cancer, rhabdomyosarcoma, ovarian cancer, pancreatic cancer, soft tissue sarcoma, and renal cell carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vinorelbine liposome.